Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving carboplatin and pemetrexed disodium together with bevacizumab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving carboplatin and pemetrexed disodium together with bevacizumab works in treating patients with stage III or stage IV non-small cell lung cancer who are light or never smokers.
Drug: erlotinib hydrochloride
Drug: pemetrexed disodium
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History|
- Progression-free survival [ Time Frame: until death ] [ Designated as safety issue: No ]Documented radiographic response per RECIST criteria each year, until subject death
- Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]Radiographic tumor response assessed by RECIST criteria.
- Subjects experiencing toxicity [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]Toxicity will be evaluated using CTCAE criteria, version 3.
|Study Start Date:||November 2010|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||November 2014 (Final data collection date for primary outcome measure)|
- To estimate the progression-free survival (PFS) of patients with advanced non-small cell lung cancer who are never or light smokers treated with carboplatin, pemetrexed disodium, and bevacizumab followed by pemetrexed disodium and bevacizumab maintenance therapy.
- To estimate the overall survival (OS) of patients treated with this regimen.
- To estimate the toxicity of treatment using the NCI CTCAE version 3.0.
- To conduct an exploratory analysis of molecular markers (e.g., KRAS and EGFR mutations) in patients with a never or light smoking history and to analyze any potential association with response, PFS, and OS.
- To assess response to second-line erlotinib hydrochloride therapy according to RECIST criteria.
OUTLINE: This is a multicenter study.
- First-line therapy: Patients receive pemetrexed disodium IV over 10 minutes, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve partial or complete response or have stable disease progress to maintenance therapy.
- Maintenance therapy: Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Patients who experience disease progression or unacceptable toxicity may receive second-line therapy with erlotinib hydrochloride as part of standard-of-care treatment.
Tissue samples are collected at baseline for laboratory biomarker analysis.
After completion of maintenance therapy, patients are followed every 4 weeks for 2 months.
|Contact: Donna Rowe, RN||(919) firstname.lastname@example.org|
|United States, North Carolina|
|Asheville, North Carolina, United States, 28801|
|Principal Investigator: Michael Messino, MD|
|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill||Recruiting|
|Chapel Hill, North Carolina, United States, 27599-7295|
|Contact: Clinical Trials Office - Lineberger Comprehensive Cancer Cente 877-668-0683|
|Leo W. Jenkins Cancer Center at ECU Medical School||Withdrawn|
|Greenville, North Carolina, United States, 27834|
|CCHC New Bern Cancer Care||Recruiting|
|New Bern, North Carolina, United States, 28562|
|Principal Investigator: Chris Taylor, MD|
|United States, Pennsylvania|
|University of Pittsburgh Medical Center||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15232|
|Principal Investigator: Liza Villaruz, MD|
|Principal Investigator:||Thomas E. Stinchcombe, MD||UNC Lineberger Comprehensive Cancer Center|